The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03652610




Registration number
NCT03652610
Ethics application status
Date submitted
28/08/2018
Date registered
29/08/2018
Date last updated
25/02/2020

Titles & IDs
Public title
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age
Scientific title
Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age
Secondary ID [1] 0 0
V59_71
Secondary ID [2] 0 0
205343
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Infections, Meningococcal 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Other interventions - Licensed GSK MenACWY vaccine (Menveo)

Experimental: GSK3536820A ACWY_Liq Group - Approximately 486 healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.

Active Comparator: ACWY Group - Approximately 486 healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK' MenACWY vaccine formulation (Menveo).


Other interventions: MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm

Other interventions: Licensed GSK MenACWY vaccine (Menveo)
Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) against N. meningitidis serogroup A for each vaccine group and between-groups ratios. - hSBA titers against N.meningitidis serogroup A are calculated in terms of GMTs.
Timepoint [1] 0 0
At Day 29
Secondary outcome [1] 0 0
hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y for each vaccine group and between-groups ratios - Geometric Mean Titers (GMTs) against each of the N. meningitidis serogroup A (except Day 29), C, W and Y
Timepoint [1] 0 0
At Day 1 and Day 29
Secondary outcome [2] 0 0
Within-group Geometric Mean Ratios (GMRs) of GMTs against each of the N.meningitidis serogroups A, C, W and Y. - Within group ratios of hSBA GMTs against each of the N.meningitidis serogroups A, C, W and Y at Day 29 compared to Day 1.
Timepoint [2] 0 0
At Day 29
Secondary outcome [3] 0 0
Percentages of subjects with =4 fold rise in hSBA antibody titers for each of the N.meningitidis serogroups A, C,W and Y for each vaccine group and between-groups differences. - The percentages of subjects with a = 4-fold rise in post-vaccination hSBA (at Day 29 compared to Day 1) and associated 2-sided 95% Clopper-Pearson CIs are computed by group and N. meningitidis serogroups A, C, W and Y. A 4-fold rise in the hSBA titers is defined as:
for individuals, whose pre-vaccination titers are < the LOD (limit of detection), the post-vaccination titers must be = 4-fold the LOD or = the LLOQ (lower of limit of quantitation) whichever is greater;
for individuals, whose pre-vaccination titers are = the LOD and = the LLOQ, the post-vaccination titres must be at least four times the LLOQ;
for individuals whose pre-vaccination titers are > the LLOQ, the post-vaccination titers must be at least four times the pre-vaccination titer.
Timepoint [3] 0 0
At Day 29
Secondary outcome [4] 0 0
Percentages of subjects with hSBA titers =8 and =LLOQ against each of the N. meningitidis serogroups A, C, W and Y for each vaccine group and between-groups differences - For each vaccine group the percentages of subjects with hSBA titer =8 and =LLOQ* and associated two-sided 95% Clopper-Pearson CIs are computed by the N. meningitidis serogroups A, C, W and Y on Day 1 and Day 29 Note*: = LLOQ is to be assessed for each serogroup if the pre-defined LLOQ value for that serogroup is >8
Timepoint [4] 0 0
At Day 1 and Day 29
Secondary outcome [5] 0 0
Number of subjects reporting any unsolicited adverse events (AEs) within 30 min after vaccination - An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
Timepoint [5] 0 0
Within 30 min after vaccination at Day 1
Secondary outcome [6] 0 0
Number of subjects reporting solicited local and systemic AEs - Number of subjects with solicited local and systemic AEs during the 7-days period (including the day of vaccination) after the vaccination.
Timepoint [6] 0 0
From Day 1 (6 hours) to Day 7 after vaccination
Secondary outcome [7] 0 0
Number of subjects reporting other indicators of reactogenicity - Number of subjects reporting other indicators of reactogenicity such as use of analgesics/antipyretics within 7 days after vaccination
Timepoint [7] 0 0
From Day 1 to Day 7 after vaccination
Secondary outcome [8] 0 0
Number of subjects reporting any unsolicited AEs - An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered with a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
Timepoint [8] 0 0
From Day 1 to Day 29 after vaccination
Secondary outcome [9] 0 0
Number of subjects reporting serious adverse events (SAEs), AEs leading to withdrawal and medically attended AEs - Medically attended AEs are defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended AE(s) is occurrence of any medically attended AE(s) regardless of intensity grade or relation to vaccination. Serious adverse event is any congenital anomaly/birth defect in the offspring of a study subject or any untoward medical occurrence that results in death or life threatening or requires hospitalization or results in disability or incapacity
Timepoint [9] 0 0
From Day 1 to Day 181 (during the entire study period)

Eligibility
Key inclusion criteria
1. Subjects who, in the opinion of the investigator, can and will comply with the
requirements of the protocol or subjects' parent(s)/Legally Acceptable
Respresentative(s) [LAR(s)] who, in the opinion of the investigator, can and will
comply, with the requirements of the protocol.

2. Written informed consent obtained from the subject/from the parents(s)/LAR(s) of the
subject prior to performance of any study specific procedure.

3. Written informed assent obtained for subjects below legal age of consent, if required
by local regulations, at the time of enrolment.

4. A male or female between, and including, =18 to =40 YoA at the time of the first
vaccination.

5. Healthy subjects as established by medical history and clinical examination before
entering into the study.

6. Female subjects of non-childbearing potential may be enrolled in the study.

- Non-childbearing potential is defined as pre-menarche, current bilateral tubal
ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.

7. Female subjects of childbearing potential may be enrolled in the study, if the
subject:

- has practiced adequate contraception for 30 days prior to vaccination, and

- has a negative pregnancy test on the day of vaccination, and

- has agreed to continue adequate contraception during the entire treatment period.
(approximately 1 month after vaccination).
Minimum age
18 Years
Maximum age
40 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Anaphylaxis following the administration of vaccine

2. Any (clinical) condition that in the judgment of the investigator would make
intramuscular injection unsafe and/or represents a contraindication to intramuscular
vaccination and blood draws.

3. Any confirmed or suspected immunosuppressive or immunodeficient condition, including
HIV infection.

4. Progressive, unstable or uncontrolled clinical conditions.

5. Hypersensitivity, including allergy, to any component of vaccines, medicinal products
or medical equipment whose use is foreseen in this study.

6. Hypersensitivity to the active substances or to any of the excipients of the vaccine,
including diphtheria toxoid (CRM197), or a life-threatening reaction after previous
administration of a vaccine containing similar components.

7. Abnormal function of the immune system resulting from:

- Clinical conditions.

- Systemic administration of corticosteroids (Per os [PO]/ Intravenous [IV]/
Intramuscular [IM]) for more than 14 consecutive days within 90 days prior to
informed consent, and until the Day 29 blood draw.

- Administration of antineoplastic and immuno-modulating agents or radiotherapy
within 90 days prior to informed consent, and until the Day 29 blood draw.

8. Received immunoglobulins or any blood products within 180 days prior to informed
consent.

9. Received an investigational or non-registered medicinal product within 30 days prior
to informed consent.

10. Any other clinical condition that, in the opinion of the investigator, might interfere
with the results of the study or pose additional risk to the subject due to
participation in the study.

11. History of any meningococcal vaccination.

12. Individuals who received any other vaccines within 7 days (for inactivated vaccines)
or 14 days (for live vaccines) prior to enrolment in this study or who are planning to
receive any vaccine within 28 days from the study vaccines*.

* In case an emergency mass vaccination for an unforeseen public health threat (e.g.:
a pandemic) is organised by the public health authorities, outside the routine
immunization program, the time period described above can be reduced if necessary for
that vaccine provided it is licensed and used according to its Summary of Product
Characteristics (SmPC) or Prescribing Information and according to the local
governmental recommendations and provided a written approval of the Sponsor is
obtained.

13. Administration of long-acting immune-modifying drugs at any time during the study
period (e.g. infliximab).

14. Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational vaccine/product. (pharmaceutical product or device).

15. Current or previous, confirmed or suspected disease caused by N. meningitidis.

16. Household contact with and/or intimate exposure to an individual with any laboratory
confirmed N. meningitidis infection within 60 days prior to study vaccination.

17. Acute disease and/or fever within 3 days prior to study vaccination. Note: enrolment
may be postponed/delayed until such transient circumstances have ended.

- Fever is defined as body temperature = 38.0°C / 100.4°F. The preferred location
for measuring temperature in this study will be the oral cavity.

- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
infection) without fever may be enrolled at the discretion of the investigator.

18. Received systemic antibiotic treatment within 3 days prior to study vaccination or
blood draw.

19. Study personnel as an immediate family or household member.

20. Pregnant or lactating women.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Blacktown
Recruitment hospital [2] 0 0
GSK Investigational Site - Kanwal
Recruitment hospital [3] 0 0
GSK Investigational Site - Gold Coast
Recruitment hospital [4] 0 0
GSK Investigational Site - Sherwood
Recruitment hospital [5] 0 0
GSK Investigational Site - Adelaide
Recruitment hospital [6] 0 0
GSK Investigational Site - Melbourne
Recruitment hospital [7] 0 0
GSK Investigational Site - Murdoch
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2259 - Kanwal
Recruitment postcode(s) [3] 0 0
4222 - Gold Coast
Recruitment postcode(s) [4] 0 0
4075 - Sherwood
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment postcode(s) [8] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Gent
Country [2] 0 0
Belgium
State/province [2] 0 0
Leuven
Country [3] 0 0
Canada
State/province [3] 0 0
British Columbia
Country [4] 0 0
Canada
State/province [4] 0 0
Nova Scotia
Country [5] 0 0
Canada
State/province [5] 0 0
Ontario
Country [6] 0 0
Canada
State/province [6] 0 0
Quebec
Country [7] 0 0
Germany
State/province [7] 0 0
Bayern
Country [8] 0 0
Germany
State/province [8] 0 0
Nordrhein-Westfalen
Country [9] 0 0
Germany
State/province [9] 0 0
Rheinland-Pfalz
Country [10] 0 0
Germany
State/province [10] 0 0
Berlin
Country [11] 0 0
Germany
State/province [11] 0 0
Hamburg
Country [12] 0 0
Italy
State/province [12] 0 0
Abruzzo
Country [13] 0 0
Italy
State/province [13] 0 0
Liguria
Country [14] 0 0
Italy
State/province [14] 0 0
Conegliano - Treviso
Country [15] 0 0
Italy
State/province [15] 0 0
Massafra (TA)

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by
meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more
than 60 countries.

The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY
vaccine with the investigational MenACWY liquid vaccine.
Trial website
https://clinicaltrials.gov/show/NCT03652610
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications